Delisting risk removed in the near term, but the one-year Discretionary Panel Monitor heightens scrutiny on future equity levels. Traders should monitor ENDRA's next 10-Q for any further decline in stockholders' equity below $2.5M, as re-triggering the deficiency would lead to immediate delisting procedures.
Price Chart
Executive Summary
ENDRA Life Sciences Inc. (NDRA) announced via an 8-K that it has received written notice from Nasdaq confirming it has regained compliance with the $2,500,000 minimum stockholders' equity requirement for continued listing, following an April 2026 deficiency letter and a May 2026 hearing. However, the company is now subject to a one-year Discretionary Panel Monitor; any future non-compliance during this period will result in immediate delisting proceedings without standard cure periods.
Key Facts
- Nasdaq Staff determined on April 20, 2026 that ENDRA's stockholders' equity was below the $2,500,000 minimum for continued listing under Rule 5550(b)(1).
- ENDRA requested a hearing on April 27, 2026, which was held on May 28, 2026.
- On July 8, 2026, Nasdaq notified ENDRA that the company has regained compliance with the Minimum Stockholders Equity Requirement.
- ENDRA will be subject to a Discretionary Panel Monitor for one year from July 1, 2026.
- If the company falls out of compliance again during the monitoring period, Nasdaq Staff will issue a Delist Determination Letter with no opportunity for a compliance plan or cure period; the company may only request a new hearing.
Financial Impact
The immediate delisting risk is avoided, preserving access to Nasdaq listing; stock price likely to stabilize. However, the one-year monitor means any future equity deficiency will trigger direct delisting proceedings without standard grace periods.
Risk Factors
- Any future drop in stockholders' equity below $2.5M during the one-year monitoring period will result in immediate delisting proceedings without standard cure periods.
- The company has only regained compliance temporarily; structural equity weakness may persist.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-076526 |
| Document: 0001213900-26-076526-index-headers.html | 0001213900-26-076526 |
| Document: 0001213900-26-076526-index.html | 0001213900-26-076526 |
| Document: 0001213900-26-076526.txt | 0001213900-26-076526 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 425 | $4.82 | awaiting T+5 | — | $4.96 (+2.93%) |
Oct 8, 2026 19d ago | 3 | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 8, 2026 19d ago | SC 13D | $5.46 $4.74 | ▼ −13.19% | ▼ −11.22% | $4.96 (−9.14%) |
Oct 1, 2026 26d ago | 425 | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Oct 1, 2026 26d ago | 8-K | $6.06 $5.46 | ▼ −9.90% | ▼ −11.06% | $4.96 (−18.14%) |
Sep 25, 2026 4w ago | 425 | $5.80 $6.31 | ▲ +8.79% | ▲ +7.59% | $4.96 (−14.47%) |
Sep 9, 2026 6w ago | 425 | $5.83 $5.13 | ▼ −12.01% | ▼ −11.67% | $4.96 (−14.91%) |
Aug 17, 2026 10w ago | 8-K | $4.51 $4.75 | ▲ +5.32% | ▲ +5.52% | $4.96 (+10.00%) |
Jul 17, 2026 14w ago | 425 | $4.99 $5.23 | ▲ +4.81% | ▲ +5.50% | $4.96 (−0.58%) |
Jul 9, 2026 15w ago | 8-K | $5.49 $5.27 | ▼ −4.01% | ▼ −3.88% | $4.96 (−9.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers